Back to News
Market Impact: 0.2
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Source: businesswire.com
Healthcare & Biotech
Puma Biotechnology initiated the Phase II ALISCA-Lung2 trial evaluating alisertib combined with paclitaxel for advanced small cell lung cancer. The clinical-trial start advances the company’s oncology pipeline, but no efficacy, safety, financial, or regulatory results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PBYI0.55
More News
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- Halozyme prices $1.3 billion convertible notes offering
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
- Why is Xenon Pharmaceuticals stock plunging today?
- Intel and Micron lead our portfolio higher, and J&J's strengthens our case for owning it
- Ultragenyx stock surges 10% on FDA approval for gene therapy